Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer

European Journal of Cardio-thoracic Surgery

Volumn 47, Issue 3, 2015, Pages 550-555

  Takenaka, Tomoyoshi ^a   Takenoyama, Mitsuhiro ^a   Yamaguchi, Masafumi ^a   Toyozawa, Ryo ^a   Inamasu, Eiko ^a   Kojo, Miyako ^a   Toyokawa, Gouji ^a   Yoshida, Tsukihisa ^a   Shiraishi, Yoshimasa ^a   Morodomi, Yosuke ^a   Hirai, Fumihiko ^a   Taguchi, Kenichi ^a   Shimokawa, Mototsugu ^a   Seto, Takashi ^a   Ichinose, Yukito ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

EGFR mutation; EGFR TKIs; Non small cell lung cancer; Post recurrence survival; Surgical resection

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EGFR PROTEIN, HUMAN;

ADRENAL METASTASIS; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE INTERVAL; ELECTROCORTICOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LUNG RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; SMOKING; SURVIVAL RATE; SURVIVAL TIME; ADULT; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MUTATION; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 84928198061     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezu227     Document Type: Article

References (23)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Hung JJ, Hsu WH, Hsieh CC, Huang BS, Huang MH, Liu JS et al. Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence. Thorax 2009;64:192-6.
3. Hung JJ, Jeng WJ, Hsu WH, Wu KJ, Chou TY, Hsieh CC et al. Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis. Thorax 2010;65:241-5.
4. Williams BA, Sugimura H, Endo C, Nichols FC, Cassivi SD, Allen MS et al. Predicting postrecurrence survival among completely resected nonsmallcell lung cancer patients. Ann Thorac Surg 2006;81:1021-7.
5. Endo C, Sakurada A, Notsuda H, Noda M, Hoshikawa Y, Okada Y et al. Results of long-term follow-up of patients with completely resected nonsmall cell lung cancer. Ann Thorac Surg 2012;93:1061-8.
6. Saisho S, Yasuda K, Maeda A, Yukawa T, Okita R, Hirami Y et al. Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy. Interact CardioVasc Thorac Surg 2013;16:166-72.
7. Shimada Y, Saji H, Yoshida K, Kakihana M, Honda H, Nomura M et al. Prognostic factors and the significance of treatment after recurrence in completely resected stage I non-small cell lung cancer. Chest 2013;143:1626-34.
8. Hung JJ, Jeng WJ, Hsu WH, Chou TY, Huang BS, Wu YC. Predictors of death, local recurrence, and distant metastasis in completely resected pathological stage-I non-small-cell lung cancer. J Thorac Oncol 2012;7:1115-23.
9. Sugimura H, Nichols FC, Yang P, Allen MS, Cassivi SD, Deschamps C et al. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg 2007;83:409-17.
10. Yano T, Haro A, Yoshida T, Morodomi Y, Ito K, Shikada Y et al. Prognostic impact of local treatment against postoperative oligometastases in nonsmall cell lung cancer. J Surg Oncol 2010;102:852-5.
11. Hishida T, Nagai K, Yoshida J, Nishimura M, Ishii G, Iwasaki Met al. Is surgical resection indicated for a solitary non-small cell lung cancer recurrence? J Thorac Cardiovasc Surg 2006;131:838-42.
12. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
13. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
14. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
15. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J et al. West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
16. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al. North-East Japan Study Group. Gefitinib or chemotherapy for non-smallcell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
17. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E et al. Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
18. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg 1975;70:606-12.
19. World Health Organization. Histological Typing of Lung and Pleural Tumors, 3rd edn. Geneva, Switzerland, Springer-Verlag, 1999.
20. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R et al. International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-14.
21. Macdermed DM, Weichselbaum RR, Salama JK. A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol 2008;98:202-6.
22. Kim YT, Seong YW, Jung YJ, Jeon YK, Park IK, Kang CH et al. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer. J Thorac Oncol 2013;8:171-8.
23. Izar B, Sequist L, Lee M, Muzikansky A, Heist R, Iafrate J et al. The impact of EGFR mutation status on outcomes in patients with resected stage I nonsmall cell lung cancers. Ann Thorac Surg 2013;96:962-8.